Company Update - Aprea Therapeutics has engaged Dr Philippe Pultar as its senior medical advisor to support the development and advancement of APR-1051, a potential best-in-class WEE1 inhibitor [1] - Dr Pultar brings extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development [2] - Dr Pultar's prior role at Zentalis Pharmaceuticals involved strategy and execution of the global clinical development of azenosertib, a WEE1 inhibitor [2] Clinical Development - Patient enrollment is ongoing in the Phase 1 ACESOT-1051 study, which assesses the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of APR-1051 in advanced solid tumors with certain cancer-associated gene alterations [3] - Aprea plans to provide an update on the progress of the ACESOT-1051 clinical study by the end of 2024 [3] - The WEE1 program is part of Aprea's portfolio of DDR-targeted therapeutics aimed at delivering precision medicine solutions [3] Leadership and Expertise - Dr Pultar has over 17 years of experience in early and late-stage clinical development, including roles at Zentalis Pharmaceuticals, Novartis Oncology, Agennix AG, and ImClone Systems [5] - Dr Pultar initiated seven Phase 1 and Phase 2 trials with azenosertib as a single agent and in combination with chemotherapy and targeted agents across multiple indications [5] - Dr Pultar's foundational education includes Medical Studies and Residency at Université de Médecine de Poitiers, France [6] Strategic Vision - Dr Pultar believes WEE1 inhibition is a promising therapeutic approach in oncology and is impressed by the progress of APR-1051, which has a differentiated profile and compelling pre-clinical data [4] - Aprea's President and CEO, Dr Oren Gilad, highlights Dr Pultar's track record of successfully leading programs through late-stage development and regulatory approval [4] - Dr Pultar's addition aligns with Aprea's strategy to bring in exceptional talent to advance its programs and maximize the therapeutic potential of APR-1051 [4] Leadership Transition - Dr Nadeem Mirza will step down as Chief Medical Officer effective October 9, 2024, but will remain with the company until no later than December 13, 2024, to ensure a smooth transition [4]

Aprea Therapeutics, Inc. (APRE) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.38%. A quarter ago, it was expected that this company would post a loss of $0.78 per share when it actually produced a loss of $0.67, delivering a surprise of 14.10%. Over the last four quarters, the company ha ...

Exhibit 99.1 Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash equivalents as of June 30, 2024 with cash runway extended into Q4 2025 DOYLESTOWN, PA, August 12, 2024 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other ...

Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash equivalents as of June 30, 2024 with cash runway extended into Q4 2025 DOYLESTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financ ...

DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To register, click here. The webinar will feature Joseph Vacca, PhD, Medicinal Chemistry Expert and Consul ...

APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represents a key advancement in Aprea's clinical pipeline DOYLESTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncolo ...

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been found to be safe and well tolerated with no dose limiting toxicities (DLTs) observed DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceuti ...

Exhibit 99.1 Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human ef icacy data in 2H 2024 Company had four poster presentations at the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39069 Aprea Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2246769 (State or other ...